DelveInsight’s “Chemotherapy Induced Peripheral Neuropathy Pipeline Insight 2026” report provides comprehensive insights about 4+ companies and 5+ pipeline drugs in the Chemotherapy Induced Peripheral Neuropathy pipeline landscape. It covers the Chemotherapy Induced Peripheral Neuropathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chemotherapy Induced Peripheral Neuropathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Chemotherapy Induced Peripheral Neuropathy Pipeline? @ Chemotherapy Induced Peripheral Neuropathy Pipeline Outlook Report

Key Takeaways from the Chemotherapy Induced Peripheral Neuropathy Pipeline Report

• In March 2026- Institut Cancerologie de l’Ouest initiated a Phase 3 study focused on the efficacy of capsaicin 179 mg patch on the intensity of CIPN-induced pain. These non-randomized studies show that more than 50% of patients have a reduction in pain intensity of more than 30%.
• In March 2026- VM Therapeutics LLC announced a study of VMD-3866 gel (the study medicine which is non-opioid, non-NSAID), an experimental new topical medicine for treating pain caused by CIPN. The goal of this study is to assess if the study medicine improves pain symptoms in patients with CIPN, and to find out the side effects of the study medicine if any.
• DelveInsight’s Chemotherapy Induced Peripheral Neuropathy Pipeline report depicts a robust space with 4+ active players working to develop 5+ pipeline therapies for Chemotherapy Induced Peripheral Neuropathy treatment.
• The leading Chemotherapy Induced Peripheral Neuropathy Companies, such as Grünenthal GmbH, AlgoTherapeutix,Wex Pharmaceuticals Inc., and others.
• Promising Chemotherapy Induced Peripheral Neuropathy Therapies such as WST-057, ATX01 10%, Capsaicin, Duloxetine, Olesoxime (TRO19622), ONO-2910, GM1, VMD-3866 Gel and others.

Want to know which companies are leading innovation in Chemotherapy Induced Peripheral Neuropathy? @ Chemotherapy Induced Peripheral Neuropathy Clinical Trials Assessment

The Chemotherapy Induced Peripheral Neuropathy Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Chemotherapy Induced Peripheral Neuropathy Pipeline Report also highlights the unmet needs with respect to the Chemotherapy Induced Peripheral Neuropathy.

Chemotherapy Induced Peripheral Neuropathy Overview

Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and complex side effect of cancer treatment, particularly with common chemotherapy drugs. It can arise during treatment, leading to dose reductions or early cessation, potentially affecting treatment effectiveness and survival outcomes. While acute CIPN often resolves after chemotherapy, in some cases, it can persist or emerge later, causing long-term symptoms. The prevalence of CIPN remains high for months after treatment, varying with the type of chemotherapy used and patient-specific factors. Despite improvements in cancer survival rates, CIPN remains a significant challenge for both patients and healthcare providers. The impact on patients’ quality of life can be profound, as symptoms like pain, tingling, and numbness affect daily functioning. Moreover, the lack of effective treatments for CIPN further complicates management, making prevention and early intervention critical.

Chemotherapy Induced Peripheral Neuropathy Emerging Drugs Profile

• Capsaicin: Grünenthal GmbH

Capsaicin (QUTENZA) is a specially formulated topical system that delivers prescription-strength capsaicin directly to the skin during an in-office procedure. This way, it can reversibly desensitise and defunctionalise the TRPV1 (Transient Receptor Potential Vanilloid 1) receptor, which plays a critical role in pain signalling. QUTENZA administered as a single localised procedure can provide sustained pain relief that lasts for up to three months. It has no known drug-drug interactions. The most common adverse reactions include application site reactions, such as erythema, pain, and pruritus. Currently, the drug is in Phase III stage of its development for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN).

• ATX01: AlgoTherapeutix

ATX01 targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channels. It has been designed to provide targeted relief from excruciating pain in the feet and hands of patients suffering from Chemotherapy-Induced Peripheral Neuropathy (CIPN). ATX01 has wide potential applicability beyond CIPN, in other diseases where peripheral neuropathic pain is a major issue. By applying the ATX01 hydrogel to the skin, the active ingredient is locally delivered to the nerve endings where pain signals originate and propagate alongside the neurons to the central nervous system. This method of application is especially relevant to CIPN which involves localized pain. Topical administration also minimizes systemic toxicity and drug interactions through limited systemic exposure, which is particularly important in patients exposed to chemotherapy. Currently, the drug is in Phase II stage of its development for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN).

If you’re tracking ongoing Chemotherapy Induced Peripheral Neuropathy Clinical trials @ Chemotherapy Induced Peripheral Neuropathy Treatment Drugs

The Chemotherapy Induced Peripheral Neuropathy Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Chemotherapy Induced Peripheral Neuropathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chemotherapy Induced Peripheral Neuropathy Treatment.
• Chemotherapy Induced Peripheral Neuropathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chemotherapy Induced Peripheral Neuropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chemotherapy Induced Peripheral Neuropathy market.

Chemotherapy Induced Peripheral Neuropathy Companies

Grünenthal GmbH, AlgoTherapeutix,Wex Pharmaceuticals Inc., and others.

Chemotherapy Induced Peripheral Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Chemotherapy Induced Peripheral Neuropathy Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Chemotherapy Induced Peripheral Neuropathy Pipeline Report @ Chemotherapy Induced Peripheral Neuropathy Market Drivers and Barriers, and Future Perspectives

Scope of the Chemotherapy Induced Peripheral Neuropathy Pipeline Report

• Coverage- Global
• Chemotherapy Induced Peripheral Neuropathy Companies- Grünenthal GmbH, AlgoTherapeutix,Wex Pharmaceuticals Inc., and others.
• Chemotherapy Induced Peripheral Neuropathy Therapies- WST-057, ATX01 10%, Capsaicin, Duloxetine, Olesoxime (TRO19622), ONO-2910, GM1, VMD-3866 Gel and others.
• Chemotherapy Induced Peripheral Neuropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chemotherapy Induced Peripheral Neuropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Chemotherapy Induced Peripheral Neuropathy Treatment landscape in this detailed analysis @ Chemotherapy Induced Peripheral Neuropathy Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Chemotherapy Induced Peripheral Neuropathy (CIPN): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chemotherapy Induced Peripheral Neuropathy (CIPN)– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Capsaicin: Grünenthal GmbH
9. Mid Stage Products (Phase II)
10. ATX01: AlgoTherapeutix
11. Early Stage Products (Phase I)
12. Drug Name: Company Name
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Chemotherapy Induced Peripheral Neuropathy (CIPN) Key Companies
17. Chemotherapy Induced Peripheral Neuropathy (CIPN) Key Products
18. Chemotherapy Induced Peripheral Neuropathy (CIPN)- Unmet Needs
19. Chemotherapy Induced Peripheral Neuropathy (CIPN)- Market Drivers and Barriers
20. Chemotherapy Induced Peripheral Neuropathy (CIPN)- Future Perspectives and Conclusion
21. Chemotherapy Induced Peripheral Neuropathy (CIPN) Analyst Views
22. Chemotherapy Induced Peripheral Neuropathy (CIPN) Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight